Graphene oxide functional nanohybrids with magnetic nanoparticles for improved vectorization of doxorubicin to neuroblastoma cells

dc.bibliographicCitation.firstPage3eng
dc.bibliographicCitation.issue1eng
dc.bibliographicCitation.lastPage182eng
dc.bibliographicCitation.volume11eng
dc.contributor.authorLerra, L.
dc.contributor.authorFarfalla, A.
dc.contributor.authorSanz, B.
dc.contributor.authorCirillo, G.
dc.contributor.authorVittorio, O.
dc.contributor.authorVoli, F.
dc.contributor.authorGrand, M.L.
dc.contributor.authorCurcio, M.
dc.contributor.authorNicoletta, F.P.
dc.contributor.authorDubrovska, A.
dc.contributor.authorHampel, S.
dc.contributor.authorIemma, F.
dc.contributor.authorGoya, G.F.
dc.date.accessioned2020-07-18T06:12:40Z
dc.date.available2020-07-18T06:12:40Z
dc.date.issued2019
dc.description.abstractWith the aim to obtain a site-specific doxorubicin (DOX) delivery in neuroblastoma SH-SY5Y cells, we designed an hybrid nanocarrier combining graphene oxide (GO) and magnetic iron oxide nanoparticles (MNPs), acting as core elements, and a curcumin–human serum albumin conjugate as functional coating. The nanohybrid, synthesized by redox reaction between the MNPs@GO system and albumin bioconjugate, consisted of MNPs@GO nanosheets homogeneously coated by the bioconjugate as verified by SEM investigations. Drug release experiments showed a pH-responsive behavior with higher release amounts in acidic (45% at pH 5.0) vs. neutral (28% at pH 7.4) environments. Cell internalization studies proved the presence of nanohybrid inside SH-SY5Y cytoplasm. The improved efficacy obtained in viability assays is given by the synergy of functional coating and MNPs constituting the nanohybrids: while curcumin moieties were able to keep low DOX cytotoxicity levels (at concentrations of 0.44–0.88 µM), the presence of MNPs allowed remote actuation on the nanohybrid by a magnetic field, increasing the dose delivered at the target site.eng
dc.description.sponsorshipLeibniz_Fondseng
dc.description.versionpublishedVersioneng
dc.identifier.urihttps://doi.org/10.34657/3632
dc.identifier.urihttps://oa.tib.eu/renate/handle/123456789/5003
dc.language.isoengeng
dc.publisherBasel : MDPI AGeng
dc.relation.doihttps://doi.org/10.3390/pharmaceutics11010003
dc.relation.ispartofseriesPharmaceutics 11 (2019), Nr. 1eng
dc.relation.issn1999-4923
dc.rights.licenseCC BY 4.0 Unportedeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/eng
dc.subjectGraphene oxideeng
dc.subjectIron oxide nanoparticleseng
dc.subjectMagnetic targetingeng
dc.subjectNanohybridseng
dc.subjectSynergismeng
dc.subjectalbumineng
dc.subjectcurcumineng
dc.subjectdoxorubicineng
dc.subjectgraphene oxideeng
dc.subjectmagnetic iron oxide nanoparticleeng
dc.subjectmagnetic nanoparticleeng
dc.subjectnanoparticleeng
dc.subjectunclassified drugeng
dc.subjectacidityeng
dc.subjectArticleeng
dc.subjectcell viabilityeng
dc.subjectconcentration (parameters)eng
dc.subjectconjugationeng
dc.subjectcontrolled studyeng
dc.subjectcytoplasmeng
dc.subjectdrug coatingeng
dc.subjectdrug cytotoxicityeng
dc.subjectdrug delivery systemeng
dc.subjecthumaneng
dc.subjecthuman celleng
dc.subjectintracellular transporteng
dc.subjectneuroblastoma celleng
dc.subjectreaction analysiseng
dc.subjectscanning electron microscopyeng
dc.subjectSH-SY5Y cell lineeng
dc.subjectsynthesiseng
dc.subject.ddc610eng
dc.titleGraphene oxide functional nanohybrids with magnetic nanoparticles for improved vectorization of doxorubicin to neuroblastoma cellseng
dc.typearticleeng
dc.typeTexteng
dcterms.bibliographicCitation.journalTitlePharmaceuticseng
tib.accessRightsopenAccesseng
wgl.contributorIFWDeng
wgl.subjectMedizin, Gesundheiteng
wgl.typeZeitschriftenartikeleng
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Lerra et al 2019, Graphene Oxide Functional Nanohybrids with Magnetic.pdf
Size:
5.51 MB
Format:
Adobe Portable Document Format
Description:
Collections